share_log

Evolent Health (NYSE:EVH) Pulls Back 5.1% This Week, but Still Delivers Shareholders Incredible 33% CAGR Over 5 Years

Evolent Health (NYSE:EVH) Pulls Back 5.1% This Week, but Still Delivers Shareholders Incredible 33% CAGR Over 5 Years

evolent health(纽交所:EVH)本周回落5.1%,但仍以惊人的33%年均复合增长率回报股东5年
Simply Wall St ·  09/06 10:32

We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing gains over the years. To wit, the Evolent Health, Inc. (NYSE:EVH) share price has soared 313% over five years. And this is just one example of the epic gains achieved by some long term investors. And in the last month, the share price has gained 49%.

我们认为所有投资者都应该尝试购买和持有优质的多年赢家。多年来,我们看到了一些真正令人惊讶的收益。以Evolent Health, Inc. (纽交所:EVH)的股价为例,其股价在过去五年中上涨了313%。这只是一些长期投资者实现的惊人收益的一个例子。最近一个月,股价上涨了49%。

While the stock has fallen 5.1% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

虽然本周股价下跌了5.1%,但值得关注的是长期而言,股票的历史回报是否受基本面驱动。

Given that Evolent Health didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

鉴于Evolent Health过去十二个月没有盈利,我们将重点关注营业收入增长,以快速了解其业务发展情况。当一家公司没有盈利时,我们通常希望看到良好的营业收入增长。有些公司愿意推迟盈利以加快收入增长,但在这种情况下,我们希望看到良好的营业收入增长来弥补缺乏盈利的情况。

For the last half decade, Evolent Health can boast revenue growth at a rate of 24% per year. That's well above most pre-profit companies. Arguably, this is well and truly reflected in the strong share price gain of 33%(per year) over the same period. It's never too late to start following a top notch stock like Evolent Health, since some long term winners go on winning for decades. On the face of it, this looks lke a good opportunity, although we note sentiment seems very positive already.

在过去的五年里,Evolent Health每年的营业收入增长率为24%。这远远高于大多数无利润公司。可以说,这完全反映在同期股价上涨33%(每年)的强劲涨幅中。像Evolent Health这样的顶级股票始终是一个不错的投资机会,因为一些长期赢家会持续赢下去几十年。从表面上看,这似乎是一个不错的机会,尽管我们注意到市场情绪已经非常积极。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下图显示了收益和营收随时间变化的情况(如果你点击图像,可以看到更多细节):

big
NYSE:EVH Earnings and Revenue Growth September 6th 2024
纽交所:EVH收益和营业收入增长 2024年9月6日

Evolent Health is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

Evolent Health在投资者中很有名,许多聪明的分析师试图预测未来的利润水平。因此,我们建议查看这份免费报告,显示共识预测。

A Different Perspective

不同的观点

Evolent Health shareholders are up 19% for the year. But that return falls short of the market. If we look back over five years, the returns are even better, coming in at 33% per year for five years. Maybe the share price is just taking a breather while the business executes on its growth strategy. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Evolent Health , and understanding them should be part of your investment process.

Evolent Health的股东今年已经增加了19%。 但是这一回报略低于市场水平。如果我们回顾过去五年,回报甚至更好,达到每年33%的水平。也许股价只是在业务执行其增长策略时稍作休息。我发现从长期来看股价作为业务表现的一种代理非常有趣。但要真正获得洞察力,我们还需要考虑其他信息。例如,投资风险随时存在。我们已经发现了2个警示信号,与Evolent Health有关,了解它们应该成为您的投资过程的一部分。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).

如果您喜欢与管理层一起购买股票,那么您可能会喜欢这个公司的免费列表。 (提示:其中许多公司不为人注意且具有吸引力的估值。)

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发